Impact of inappropriate antimicrobial therapy on patients with bacteremia in intensive care units and resistance patterns in Latin America

Revista Argentina de Microbiologia

Volumn 42, Issue 3, 2010, Pages 230-234

  Cortes J A ^a   Garzon D C ^a   Navarrete, J A ^a   Contreras, K M ^a  

^a UNIVERSIDAD NACIONAL DE COLOMBIA   (Colombia)

Author keywords

Antimicrobial drug resistance; Bacteremia; Intensive care units; Latin America; Nosocomial infection

Indexed keywords

IMIPENEM; OXACILLIN;

ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL THERAPY; BACTEREMIA; DRUG SURVEILLANCE PROGRAM; ESCHERICHIA COLI; HOSPITAL INFECTION; HUMAN; INTENSIVE CARE UNIT; KLEBSIELLA; LENGTH OF STAY; NONHUMAN; PSEUDOMONAS AERUGINOSA; REVIEW; SOUTH AND CENTRAL AMERICA; STAPHYLOCOCCUS AUREUS;

ANTI-INFECTIVE AGENTS; BACTEREMIA; DRUG RESISTANCE, BACTERIAL; HUMANS; INAPPROPRIATE PRESCRIBING; INTENSIVE CARE UNITS; LATIN AMERICA;

EID: 77958065759     PISSN: 03257541     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (33)

1. American Thoracic Society. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005; 171: 388-416. (Pubitemid 40227463)
2. Biedenbach DJ, Moet GJ, Jones RN. Occurrence and antimicrobial resistance pattern comparisons among bloodstream infection isolates from the SENTRY Antimicrobial Surveillance Program (1997-2002). Diagn Microbiol Infect Dis 2004; 50: 59-69.
3. Cheong HS, Kang CI, Wi YM, Kim ES, Lee JS, Ko KS, et al. Clinical significance and predictors of community-onset Pseudomonas aeruginosa bacteremia. Am J Med 2008; 121: 709-14.
4. Chrischilles EA, Scholz DA. Dollars and sense: a practical guide to cost analysis for hospital epidemiology and infection control. Clin Perform Qual Health Care 1999; 7: 107-11.
5. Cortés JA, Buitrago G, Leal AL, Junca A, Garzón D, Contreras K, et al. Etiología de las bacteriemias en pacientes críticos en Colombia, 2001-2007. Acta Med Colomb 2008; 33: 122.
6. Diekema DJ, Beekmann SE, Chapin KC, Morel KA, Munson E, Doern GV. Epidemiology and outcome of nosocomial and community-onset bloodstream infection. J Clin Microbiol 2003; 41: 3655-60. (Pubitemid 36994698)
7. Dimick JB, Pelz RK, Consunji R, Swoboda SM, Hendrix CW, Lipsett PA. Increased resource use associated with catheter-related bloodstream infection in the surgical intensive care unit. Arch Surg 2001;136: 229-34.
8. Falagas ME, Kasiakou SK, Rafailidis PI, Zouglakis G, Morfou P. Comparison of mortality of patients with Acinetobacter baumannii bacteremia receiving appropriate and inappropriate empirical therapy. J Antimicrob Chemother 2006; 57: 1251-4.
9. Garrouste-Orgeas M, Timsit JF, Tafflet M, Misset B, Zahar JR, Soufir L, et al. Excess risk of death from intensive care unit-acquired nosocomial bloodstream infections: a reappraisal. Clin Infect Dis 2006; 42: 1118-26.
10. González-Salvatierra R, Guzmán-Blanco M. Conferencia Panamericana de Resistencia Antimicrobiana en la Américas. Rev Panam Infectol 1999; 3: S1-5.
11. Harbarth S, Nobre V, Pittet D. Does antibiotic selection impact patient outcome? Clin Infect Dis 2007; 44: 87-93.
12. Kang CI, Kim SH, Kim HB, Park SW, Choe YJ, Oh MD, et al. Pseudomonas aeruginosa bacteremia: risk factors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome. Clin Infect Dis 2003; 37: 745-51.
13. Kang CI, Kim SH, Park WB, Lee KD, Kim HB, Kim EC, et al. Bloodstream infections caused by antibiotic-resistant gram-negative bacilli: risk factors for mortality and impact of inappropriate initial antimicrobial therapy on outcome. Antimicrob Agents Chemother 2005; 49: 760-6.
14. Kang CI, Kim SH, Park WB, Lee KD, Kim HB, Kim EC, et al. Bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy. Antimicrob Agents Chemother 2004; 48: 4574-81.
15. Kardas P, Pechere JC, Hughes DA, Cornaglia G. A global survey of antibiotic leftovers in the outpatient setting. Int J Antimicrob Agents 2007; 30: 530-6. (Pubitemid 350051782)
16. Khatib R, Saeed S, Sharma M, Riederer K, Fakih MG, Johnson LB. Impact of initial antibiotic choice and delayed appropriate treatment on the outcome of Staphylococcus aureus bacteremia. Eur J Clin Microbiol Infect Dis 2006; 25: 181-5.
17. Kim SH, Park WB, Lee CS, Kang CI, Bang JW, Kim HB, et al. Outcome of inappropriate empirical antibiotic therapy in patients with Staphylococcus aureus bacteraemia: analytical strategy using propensity scores. Clin Microbiol Infect 2006;12: 13-21.
18. Kuti EL, Patel AA, Coleman CI. Impact of inappropriate antibiotic therapy on mortality in patients with ventilator-associated pneumonia and bloodstream infection: a meta-analysis. J Crit Care 2008; 23: 91-100.
19. Laupland KB, Lee H, Gregson DB, Manns BJ. Cost of intensive care unit-acquired bloodstream infections. J Hosp Infect 2006; 63: 124-32.
20. Lin MY, Weinstein RA, Hota B. Delay of active antimicrobial therapy and mortality among patients with bacteremia: impact of severe neutropenia. Antimicrob Agents Chemother 2008; 52: 3188-94.
21. Lodise TP, McKinnon PS, Swiderski L, Rybak MJ. Outcome analysis of delayed antibiotic treatment for hospital-acquired Staphylococcus aureus bacteremia. Clin Infect Dis 2003; 36: 1418-23.
22. McGowan JE, Jr. Economic impact of antimicrobial resistance. Emerg Infect Dis 2001; 7: 286-92.
23. Micek ST, Lloyd AE, Ritchie DJ, Reichley RM, Fraser VJ, Kollef MH. Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatment. Antimicrob Agents Chemother 2005; 49: 1306-11.
24. Miranda MC, Perez F, Zuluaga T, Olivera M del R, Correa A, Reyes SL, et al. Antimicrobial resistance in gram-negative bacteria isolated from intensive care units of Colombian hospitals, WHONET 2003, 2004 and 2005. Biomedica 2006; 26: 424-33.
25. Multicenter study on self-medication and self-prescription in six Latin American countries. Drug Utilization Research Group, Latin America. Clin Pharmacol Ther 1997; 61: 488-93.
26. Ocaña Carrizo AV, Rocchi M, Gasparotto A, Conrero I, Navarro M, Factorovich S, et al. Bacteremia by enterobacteria in adults from a university hospital: a five year analysis. Rev Argent Microbiol 2007; 39: 38-43. (Pubitemid 46725184)
27. OPS. Protocolo para determinar el costo de la infección intrahospitalria, 2007. Available from: www.ops-oms.org/Spanish/AD/DPC/CD/ protocolo.pdf. (Consulted: November 15, 2008).
28. Sader HS, Jones RN, Gales AC, Silva JB, Pignatari AC. SENTRY antimicrobial surveillance program report: Latin American and Brazilian results for 1997 through 2001. Braz J Infect Dis 2004; 8: 25-79.
29. Thom KA, Schweizer ML, Osih RB, McGregor JC, Furuno JP, Perencevich EN, et al. Impact of empiric antimicrobial therapy on outcomes in patients with Escherichia coli and Klebsiella pneumoniae bacteremia: a cohort study. BMC Infect Dis 2008; 8: 116.
30. Vandijck DM, Depaemelaere M, Labeau SO, Depuydt PO, Annemans L, Buyle FM, et al. Daily cost of antimicrobial therapy in patients with intensive care unit-acquired, laboratory-confirmed bloodstream infection. Int J Antimicrob Agents 2008; 31: 161-5.
31. Wang FD, Chen YY, Chen TL, Liu CY. Risk factors and mortality in patients with nosocomial Staphylococcus aureus bacteremia. Am J Infect Control 2008; 36: 118-22.
32. Wenzel RP, Thompson RL, Landry SM, Russell BS, Miller PJ, Ponce de Leon S, et al. Hospital-acquired infections in intensive care unit patients: an overview with emphasis on epidemics. Infect Control 1983; 4: 371-5.
33. Wolff MJ. Use and misuse of antibiotics in Latin America. Clin Infect Dis 1993; 17 Suppl 2: S346-51.